Anaplastic lymphoma kinase (ALK) is a potent oncogenic driver in lung cancer. ALK tyrosine kinase inhibitors yield significant benefit in patients with ALK fusion-positive (ALK+) lung cancers; yet the durability of response is limited by drug resistance.
针对淋巴瘤来说,也有部分研究发现克唑替尼(Crizotinib)对ALK阳性淋巴瘤有效。在淋巴造血系统中,ALK阳性的疾病主要包括ALK阳性间变大细胞淋巴瘤(ALK-positive anaplastic large cell lymphoma, ALCL), ALK阳性大B细胞淋巴瘤 (ALK-positive large B cell lymphoma),以及ALK阳性组织细胞增生症(ALK-positive histiocytosis)...
[9] Nishio A M , Yoshida B T , Kumagai C T , et al. Brigatinib in Japanese Patients With ALK–Positive Non–Small Cell Lung Cancer Previously Treated With Alectinib and Other Tyrosine Kinase Inhibitors: Outcomes of the Phase 2 J-ALTA Trial[...
[6].X. Yang, et al. Alectinib in patients with ALK-positive advanced non-small cell lung cancer as first-line or sequential treatment in China. 2020 WCLC Abstract 2487. [7].Intracranial efficacy of Alectinib in ALK-positive NSCLC patients...
[5] Shaw A T, Bauer T M, Marinis F D, et al. First-Line Lorlatinib or Crizotinib in Advanced ALK -Positive Lung Cancer[J]. New England Journal of Medicine, 2020, 383(21):2018-2029. [6] Yang Y, Zhou J, Zhou J, et al. Efficacy, safety, and biomarker analysis of ensartini...
https://u.wechat.com/MFyT_vWQMAlv6-sjlOt1LHs (二维码自动识别) 参考文献: Yi-Long Wu, M.D, et al., Alectinib in Resected ALK-Positive Non–Small-Cell Lung Cancer, N Engl J Med 2024;
了解更多关于肿瘤诊疗的信息。希望这个病例能够给其他患者带来希望和启示，让更多人了解和应用这些治疗方法，提高治愈的机会和生存质量。参考文献：Qi Song, et al., Neoadjuvant immunotherapy plus chemotherapy and adjuvant targeted therapy in ALK-positive non-small-cell lung cancer, Immunotherapy (2023).
[2]Consensus on diagnosis for ALK positive non-small cell lung cancer in China, the 2013 version.[3]NCCN Guidelines Version 5.2022 Non-Small Cell Lung Cancer.[4]Final Overall Survival Analysis From a Study Comparing First-Line Crizotinib Versus Chemotherapy in ALK-Mutation-Positive Non-Small-...
6、Camidge D R, Dziadziuszko R, Peters S, et al. Updated efficacy and safety data and impact of the EML4-ALK fusion variant on the efficacy of alectinib in untreated ALK-positive advanced non–small cell lung cancer in the global phase III ALEX study[J]. Journal of Thoracic Oncology, ...
对于基因检测报告的分析和解读，正规的基因检测公司会给出明确的指导。#肺癌# 参考文献：Zhang SS, et al., Going beneath the tip of the iceberg. Identifying and understanding EML4-ALK variants and TP53 mutations to optimize treatment of ALK fusion positive (ALK+) NSCLC, Lung Cancer (2021)